Investor Presentaiton

Revenue by Segments Generics Biosimilars $ Biocon Income1 Q3 FY21 Q3 FY20 Growth 9M FY21 9MFY20 Growth 561 576 (3%) 1,758 1,645 7% 769 693 11% 2,137 1,882 14% Novel Biologics Research Services 585 519 13% 1,526 1,405 9% Revenue from Operations 1,851 1,717 8% 5,267 4,743 11% Other Income 28 36 (22%) 56 98 (43%) TOTAL REVENUE 1,879 1,753 7% 5,323 4,841 10% 11 9 32 23 THE *Licensing Income 1. All Figures in Crore except % Touching a billion lives through affordable innovation 15

View entire presentation